97-12256. Agency Information Collection Activities; Submission for OMB Review; Comment Request  

  • [Federal Register Volume 62, Number 90 (Friday, May 9, 1997)]
    [Notices]
    [Pages 25632-25633]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-12256]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 97N-0158]
    
    
    Agency Information Collection Activities; Submission for OMB 
    Review; Comment Request
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    [[Page 25633]]
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing that the 
    proposed collection of information listed below has been submitted to 
    the Office of Management and Budget (OMB) for review and clearance 
    under the Paperwork Reduction Act of 1995 (the PRA).
    DATES: Submit written comments on the collection of information by June 
    9, 1997.
    
    ADDRESSES: Submit written comments on the collection of information to 
    the Office of Information and Regulatory Affairs, OMB, New Executive 
    Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: 
    Desk Officer for FDA.
    FOR FURTHER INFORMATION CONTACT: Margaret R. Wolff, Office of 
    Information Resources Management (HFA-250), Food and Drug 
    Administration, 5600 Fishers Lane, rm. 16B-19, Rockville, MD 20857, 
    301-827-1223.
    
    SUPPLEMENTARY INFORMATION: In compliance with section 3507 of the PRA 
    (44 U.S.C. 3507), FDA has submitted the following proposed collection 
    of information to OMB for review and clearance.
    
    Petitions for Affirmation of Generally Recognized As Safe (GRAS) 
    Status--21 CFR 170.35(c)(1)--(OMB Control Number 0910-0132--
    Reinstatement)
    
        Under authority of sections 201, 402, 409, and 701 of the Federal 
    Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321, 342, 348, and 
    371), FDA reviews petitions for affirmation as GRAS which are submitted 
    on a voluntary basis by the food industry and other interested parties. 
    Under section 409 of the act, the agency has the authority to regulate 
    food additives. Section 201(s) of the act defines ``food additive'' and 
    expressly excludes from the definitions substances GRAS for use in 
    food.
        Specifically under section 201(s) of the act, a substance is GRAS 
    if it is generally recognized among experts qualified by scientific 
    training and experience to evaluate its safety, to be safe either 
    through scientific procedures or through common use in food before 
    1958. The act has historically been interpreted to permit food 
    manufacturers to make their own determination that use of a substance 
    in food is GRAS. To implement the GRAS provisions of the act, FDA has 
    issued procedural regulations under Sec. 170.35(c)(1) (21 CFR 
    170.35(c)(1)). These regulations establish a process by which a person 
    may obtain FDA concurrence with a GRAS determination; this concurrence 
    is referred to as ``GRAS affirmation.'' These regulation set forth the 
    information to be submitted to FDA to obtain agency concurrence that a 
    substance is GRAS (Sec. 170.35(c)(1)).
        GRAS petitions are reviewed by FDA to ascertain whether the 
    available data establish that the intended use of the substance is GRAS 
    based upon either a history of the safe use of the substance before 
    1958, or upon widely available safety data (scientific procedures). The 
    GRAS affirmation process is a voluntary one, and there is some risk 
    that FDA may not agree with the petitioner's GRAS determination. The 
    GRAS petition process does provide a public procedure for coordinating 
    GRAS determinations. The process reduces the potential for public 
    health problems when substances are marketed based upon unwarranted 
    safety determinations and allows a food manufacturer to rely on the 
    lawful status of a substance that has been affirmed by FDA as GRAS.
        FDA estimates the burden of this collection of information as 
    follows:
    
                                            Estimated Annual Reporting Burden                                       
    ----------------------------------------------------------------------------------------------------------------
                               No. of       Annual Frequency    Total Annual                                        
       21 CFR Section        Respondents      per Response        Responses      Hours per Response    Total Hours  
    ----------------------------------------------------------------------------------------------------------------
    170.35(c)(1)........         5                 1                 5             2,614 (average)     13,070       
    ----------------------------------------------------------------------------------------------------------------
    There are no capital costs or operating and maintenance costs associated with this collection.                  
    
    
        Dated: May 2, 1997.
    William K. Hubbard,
    Associate Commissioner for Policy Coordination.
    [FR Doc. 97-12256 Filed 5-8-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
05/09/1997
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
97-12256
Dates:
Submit written comments on the collection of information by June 9, 1997.
Pages:
25632-25633 (2 pages)
Docket Numbers:
Docket No. 97N-0158
PDF File:
97-12256.pdf